Trial Profile
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Savolitinib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 26 Dec 2019 Status changed from recruiting to completed.
- 19 Feb 2017 Planned initiation date changed from 1 Sep 2015 to 1 Mar 2017.
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Q3 2015 with estimated completion date as Q1 2018.